US20040048315A1 - Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof - Google Patents

Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof Download PDF

Info

Publication number
US20040048315A1
US20040048315A1 US10/646,798 US64679803A US2004048315A1 US 20040048315 A1 US20040048315 A1 US 20040048315A1 US 64679803 A US64679803 A US 64679803A US 2004048315 A1 US2004048315 A1 US 2004048315A1
Authority
US
United States
Prior art keywords
buffer
impurity
growth hormone
concentration
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/646,798
Other languages
English (en)
Inventor
Anurag Rathore
Stephen Lyle
David Steinmeyer
Scott Allen
John Meyer
Denis Boyle
John Buckley
Gary Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to US10/646,798 priority Critical patent/US20040048315A1/en
Priority to EP03799266A priority patent/EP1546185B1/en
Priority to RU2005109388/13A priority patent/RU2337920C2/ru
Priority to SI200331584T priority patent/SI1546185T1/sl
Priority to BRPI0313829-1A priority patent/BRPI0313829B1/pt
Priority to MXPA05002359A priority patent/MXPA05002359A/es
Priority to CN03824791.7A priority patent/CN1697839B/zh
Priority to CA2497146A priority patent/CA2497146C/en
Priority to PT03799266T priority patent/PT1546185E/pt
Priority to KR1020057003458A priority patent/KR101176588B1/ko
Priority to PL374917A priority patent/PL211502B1/pl
Priority to JP2004541486A priority patent/JP4312154B2/ja
Priority to AT03799266T priority patent/ATE428721T1/de
Priority to ES03799266T priority patent/ES2323586T3/es
Priority to DE60327228T priority patent/DE60327228D1/de
Priority to DK03799266T priority patent/DK1546185T3/da
Priority to PCT/US2003/026498 priority patent/WO2004031213A1/en
Priority to AU2003260045A priority patent/AU2003260045B2/en
Priority to TW095130368A priority patent/TW200700553A/zh
Priority to TW092123686A priority patent/TWI289603B/zh
Priority to CN038253097A priority patent/CN1703421B/zh
Priority to KR1020057004785A priority patent/KR101120130B1/ko
Priority to TW92126051A priority patent/TWI318629B/zh
Priority to ARP030103444 priority patent/AR041350A1/es
Priority to DK03754774.2T priority patent/DK1545428T3/da
Priority to DE60330787T priority patent/DE60330787D1/de
Priority to SI200331730T priority patent/SI1545428T1/sl
Priority to AT03754774T priority patent/ATE453662T1/de
Priority to PCT/US2003/029546 priority patent/WO2004026251A2/en
Priority to PL375443A priority patent/PL212726B1/pl
Priority to MXPA05003121A priority patent/MXPA05003121A/es
Priority to RU2005113152/13A priority patent/RU2368619C2/ru
Priority to EP03754774A priority patent/EP1545428B1/en
Priority to PT03754774T priority patent/PT1545428E/pt
Priority to ES03754774T priority patent/ES2337041T3/es
Priority to BRPI0314120A priority patent/BRPI0314120B8/pt
Priority to CA2498886A priority patent/CA2498886C/en
Priority to AU2003272585A priority patent/AU2003272585B2/en
Priority to JP2004538262A priority patent/JP4633463B2/ja
Publication of US20040048315A1 publication Critical patent/US20040048315A1/en
Priority to IL167121A priority patent/IL167121A/en
Priority to IL167538A priority patent/IL167538A/en
Priority to HK05111804.8A priority patent/HK1077074A1/xx
Priority to HK05112085.6A priority patent/HK1079798B/zh
Assigned to PHARMACIA CORPORATION reassignment PHARMACIA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RATHORE, ANURAG S., MEYER, JOHN R., ALLEN, SCOTT I., BOYLE, DENIS M., BUCKLEY, JOHN J., JOHNSON, GARY V., LYLE, STEPHEN B., STEINMEYER, DAVID E.
Priority to US12/405,857 priority patent/US8148331B2/en
Priority to CY20091100660T priority patent/CY1109167T1/el
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Definitions

  • the present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof.
  • the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof.
  • the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.
  • Pegvisomant (Somavert®; Pharmacia Corp.) is a human growth hormone receptor antagonist. It is an analog of human growth hormone (“hGH”) that has been structurally altered.
  • the amino acid sequence of the protein component/intermediate (B-2036) of pegvisomant differs from the amino acid sequence of hGH at nine positions. The specific amino acid substitutions are as follows: H18D, H21N, G120K, R167N, K168A, D171S, K172R, E174S, and 1179T.
  • the first letter i.e., H18D
  • the first letter represents the amino acid in the sequence of hGH at the numbered position (i.e., 18 th amino acid position as indicated by H18D) which is substituted with the amino acid designated by the second letter (i.e., H18D). Therefore, H18D designates a substitution of the amino acid his by the amino acid asp at the 18 th amino acid position of the wild-type hGH amino acid sequence.
  • FIG. 1A schematically shows the amino acid sequence structure of the protein component/intermediate (B-2036) of pegvisomant (PEG B-2036) with asterisks indicating the potential sites of polyethylene glycol polymer (“PEG” unit) attachment.
  • the amino acid sequence listing of the protein component/intermediate (B-2036—without PEG unit attachment) of pegvisomant is identified herein as SEQ. ID. NO. 1.
  • the amino acid sequence listing of human growth hormone is identified herein as SEQ. ID. NO. 2. Both sequence listings are provided herewith.
  • pegvisomant is a protein (containing 191 amino acid residues) to which predominantly 4 to 6 PEG units are covalently bound.
  • the molecular weight of the protein component/intermediate (B-2036) of pegvisomant is 21,998 Daltons.
  • the molecular weight of each PEG unit of pegvisomant is approximately 5000 Daltons. Thereby the predominant molecular weights of pegvisomant are approximately 42,000 (4 PEG units/molecule), 47,000 (5 PEG units/molecule) and 52,000 (6 PEG units/molecule) Daltons.
  • hGH activates its receptors when a single hGH molecule binds to two of its adjacent (and identical) receptor molecules, inducing hormone-mediated receptor homodimerization. See U.S. Pat. Nos. 5,849,535 and 6,057,292.
  • the activity of hGH depends on its ability to bind two of its adjacent (and identical) receptors across two separate binding sites (site 1 and site 2) on the same hGH molecule.
  • site 1 and site 2 are numbered 1 and 2 to reflect the order of their binding to two adjacent (and identical) hGH receptors which mediate hGH-dependent homodimerization.
  • pegvisomant selectively binds to human growth hormone receptors (“GH receptors”) on cell surfaces, where it blocks the binding of endogenous human growth hormone, thereby interfering with human growth hormone signal transduction.
  • GH receptors human growth hormone receptors
  • the structural modifications to the protein portion (also called “component” or “intermediate”) of pegvisomant (relative to hGH) allow pegvisomant to competitively block interaction between an hGH molecule and an hGH receptor.
  • Pegvisomant binds to the GH receptor, therefore, blocking GH binding since the receptor is occupied.
  • the structural modifications prevent receptor dimerization, as a result signal transduction does not occur. By so blocking the required close interaction between an hGH molecule and an hGH receptor, pegvisomant blocks the hGH-mediated homodimerization of the hGH receptors, giving pegvisomant its antagonist activity.
  • This antagonist is used to treat conditions, including, but not limited to, acromegaly in patients who do not adequately respond to surgery, radiation therapy, and/or other conventional medical therapies, or who cannot otherwise tolerate these therapies.
  • the structural modifications to the protein portion (B-2036) of pegvisomant cause it to exhibit a binding affinity for the prolactin receptor which is lower than that of hGH, thereby minimizing the undesirable lactation-related side effects associated with the use of pegvisomant.
  • the protein intermediate portion (B-2036) of pegvisomant is synthesized by a strain of Escherichia coli bacteria that has been genetically modified by the addition of a plasmid that carries a gene for the growth hormone receptor antagonist (B-2036). B-2036 is then recovered from the microbial cells and purified. The purified B-2036 is then pegylated to produce pegvisomant (PEG B-2036).
  • 5,849,535 and 6,057,292 describe methods of making B-2036 and methods for conjugating one or more PEG units to B-2036, albeit without details as to how to decrease, reduce, eliminate, reverse and/or prevent the formation of unacceptably high levels of the trisulfide and des-phe isoform impurities thereof.
  • the des-phe isoform impurity is one wherein the B-2036 molecule is missing its amino-terminal phenylalanine. See FIG. 1A depicting the subject amino-terminal phenylalanine residue (i.e., indicated by the letter “F”) adjacent the —NH 2 end of B-2036.
  • the trisulfide isoform impurity is one wherein the B-2036 molecule contains an extra sulfur atom that forms a “trisulfide bridge” within the molecule. See box in FIG. 1B.
  • isoform impurities typically are generated during cell growth (e.g., fermentation) and expression (synthesis and secretion) of B-2036 in genetically modified host cells, and/or during extraction and purification of the B-2036 protein.
  • WO 94/24157 further states that this hGH trisulfide variant can be converted back to its native hGH form by treating the hGH trisulfide variant with a mercapto compound such as cysteine, glutathione, 2-mercapto ethanol or dithiothreitol. See WO 94/24157 at pages 4 and 5.
  • a mercapto compound such as cysteine, glutathione, 2-mercapto ethanol or dithiothreitol.
  • the invention is based on the novel and unexpected finding that the amount of trisulfides in the production of recombinant peptides could be reduced by the addition of a metal salt, preferably in excess, already during or after fermentation and not, as earlier suggested, by conversion of the formed trisulfides of growth hormone into the native form.” (Emphasis added.) See WO 00/02900 at page 2, lines 21-27.
  • WO 00/02900 further states “[t]he protein can be any recombinant protein but is preferably recombinant growth hormone which can be both human and animal such as human growth hormone (hGH), bovine growth hormone (bGH) and porcine growth hormone (pGH).” (Emphasis added.) See WO 00/02900 at page 3, lines 4-6.
  • hGH human growth hormone
  • bGH bovine growth hormone
  • pGH porcine growth hormone
  • the one or more reducing agents used are selected from the group consisting of, dithiothrietol (DTT); dithioerythritol (DTE); Cysteine (Cys) and Tris 2-carboxyethyphosphine (TCEP).” (Emphasis added.) See WO 02/057478 from page 3, line 24 to page 4, line 4.
  • FIG. 1A depicts the amino acid sequence of B-2036 which corresponds to SEQ. ID. NO. 1.
  • the asterisks (*) in FIG. 1A indicate nine (9) potential sites for covalent attachment of PEG units to each molecule of B-2036. Note that while nine (9) possible sites are identified, not all 9 sites have to be covalently bound to PEG units. Preferably, there are 4-6 PEG units per B-2036 molecule.
  • FIG. 1B depicts the structure of the trisulfide isoform impurity of B-2036 (designated “Trisulphide (+32 amu”)) as compared to its desirable form (designated “Native GHA”).
  • the present invention is directed to an improved processes or for producing recombinant growth hormone (including, but not limited to, human growth hormone) and recombinant growth hormone antagonist (including, but not limited to, human growth hormone antagonist) with decreased levels of their des-phe and/or trisulfide isoform impurities.
  • recombinant growth hormone including, but not limited to hGH
  • formation of its des-phe isoform impurity is decreased by sufficient addition of (1) a chelating agent or (2) a metal salt, respectively.
  • recombinant growth hormone antagonist including, but not limited to, human growth hormone antagonist
  • its trisulfide isoform impurity is decreased by sufficient contact between the trisulfide isoform impurity and (1) a mercapto compound, (2) a chelating agent, (3) a metal salt, (4) a mercapto compound together with a metal salt, or (5) a mercapto compound after contact with a chelating agent but in the absence of the chelating agent, respectively.
  • recombinant growth hormone antagonist including, but not limited to, human growth hormone antagonist
  • formation of its des-phe isoform impurity is decreased by addition of (1) a chelating agent or (2) a metal salt, respectively.
  • growth hormone antagonist and “growth hormone receptor antagonist” include (but are not limited to) polypeptides that inhibit or otherwise antagonize the binding of growth hormone to its growth hormone receptor to block the biological effect(s) of growth hormone.
  • the “growth hormone antagonist” or the “growth hormone receptor antagonist” is B-2036 or a variant thereof.
  • variants include, but are not limited to, homologues (particularly homologues with conservative amino acid substitutions, additions or deletions relative to B-2036), analogues, fragments, pseudopeptides, antibodies, etc. thereof (respectively) having growth hormone receptor antagonist activity.
  • growth hormone agonist and “growth hormone receptor agonist” include (but are not limited to) polypeptides that bind to and activate its growth hormone receptor.
  • the “growth hormone agonist” or the “growth hormone receptor agonist” is human growth hormone or a variant thereof.
  • variants include, but are not limited to, homologues (particularly homologues with conservative amino acid substitutions, additions or deletions relative to human growth hormone), analogues, fragments, pseudopeptides, antibodies, etc. (respectively) having growth hormone receptor agonist activity.
  • GROWTH HORMONE AND ANTAGONIST THEREOF refers to growth hormone agonist (i.e., “GROWTH HORMONE”) and growth hormone antagonist (i.e., “AND ANTAGONIST THEREOF”).
  • the term “and” may mean “and” or “or” as appropriate or necessary to recite a process to yield the desired decrease in the level of the relevant impurity (e.g., trisulfide or des-phe isoform impurity).
  • the term “or” may mean “and” or “or” as appropriate or necessary to recite a process to yield the desired decrease in the level of the relevant impurity (e.g., trisulfide or des-phe isoform impurity).
  • the term “decrease” means to eliminate, minimize, reduce, prevent and/or attenuate the amount of the relevant isoform impurity, whether it be the trisulfide isoform impurity or the des-phe isoform impurity.
  • the term “host cell” refers to any host cell in which recombinant B-2036 or recombinant hGH may be formed. Accordingly, the host cell may be a mammalian host cell, a plant host cell, or a microbial host cell such as E. coli . or even yeast cells. It is important to note that the host cell be one that is sufficient to grow the desired recombinant B-2036 protein component or recombinant hGH therein. As such, there is no limitation as to what the host cell may be except that it be one capable of recombinantly producing the B-2036 protein component or recombinant hGH of interest or “variants” thereof.
  • the term “growing” includes, but is not limited to, fermenting and culturing, or otherwise causing the host cell(s) to proliferate sufficiently to produce desired amounts of the recombinant B-2036 protein component or recombinant hGH.
  • recombinant B-2036 and recombinant PEG B-2036, unless indicated otherwise, it is understood that the subject invention may be used with any recombinant growth hormone agonist, recombinant growth hormone antagonist, whether it be mammalian growth hormone or its antagonist, human growth hormone or its antagonist, or bovine growth hormone or its antagonist, etc.
  • Pegvisomant is the pegylated form of recombinant protein (B-2036) produced in recombinant host cells (e.g., recombinant, genetically modified E. coli . host cells).
  • the B-2036 protein is produced during cell growth (e.g., by fermentation) and expression (synthesis and secretion). After its production, B-2036 is isolated (e.g., by homogenization) followed by purification (e.g., by extraction, centrifugation, reverse phase and anion-exchange chromatography, and buffer exchange).
  • undesirable isoform impurities of B-2036 are formed, which are the trisulfide and the des-phe isoform impurities of B-2036.
  • FIG. 1A illustrates the amino acid sequence of B-2036 with the standard 1-letter abbreviations indicating which amino acid is present at each lettered position. For reference, see Table 1 below indicating the correspondence between the letter and its associated amino acid.
  • TABLE 1 Polypeptide Amino Acid Ala A) Glu (E) Gln (Q) Asp (D) Asn (N) Leu (L) Gly (G) Lys (K) Ser (S) Val (V) Arg (R) Thr (T) Pro (P) Ile (I) Met (M) Phe (F) Tyr (Y) Cys (C) Trp (W) His (H)
  • amino acid sequence of B-2036 is provided herein as SEQ. ID. NO. 1 and the amino acid sequence hGH is provided herein as SEQ. ID. NO. 2.
  • FIG. 1B illustrates the amino acid sequence structure of the trisulfide isoform impurity of B-2036.
  • the trisulfide isoform impurity contains an extra sulfur atom in the bridge between the cysteines at positions 182 and 189 of the B-2036 protein component.
  • the mercapto compound(s) is/are added to the host cell(s) synthesizing the desired recombinant B-2036 protein component during or after (or during and after) growth of the host cell(s). Furthermore, after the growing and contacting steps have been conducted, it is preferred to purify the B-2036 protein. Thereafter, the purified protein is preferably pegylated to yield PEG B-2036 (pegvisomant). For pegylation procedures see U.S. Pat. No. 5,849,535.
  • Any mercapto compound may be used in connection with the present invention which, when contacted (preferably, with adequate mixing) with the B-2036 protein component together with its trisulfide isoform impurity, is one that is sufficient to decrease the level of the trisulfide isoform impurity, preferably without degrading (or substantially degrading) the yield of B-2036.
  • Preferred mercapto compounds suitable for use with the present invention include, but are not limited to, sulfites, glutathione, beta-mercaptoethanol, dithiothreitol, mercaptoethylamine, dithioerythritol, tris(2-carboxyethyl) phosphine hydrochloride, cysteine, and cysteine in combination with cystine.
  • cysteine or cysteine in combination with cystine (dimerized cysteine)
  • the amount of cysteine or combination of cysteine and cystine (dimerized cysteine, if any) that is suitable for use with the present invention should be that amount which is sufficient to decrease the trisulfide isoform impurity by at least about 10% of its highest equilibrium concentration (or its highest average equilibrium concentration, where multiple batches are averaged) formed.
  • the decrease in the amount of the trisulfide isoform impurity is least about 20%, 30%, 40%, or 50%, respectively, of its highest equilibrium concentration (or its highest average equilibrium concentration) formed.
  • the initial combined concentration of cysteine and any cystine suitable for use with the present invention is preferably at least about 0.1 mM, from about 0.1 mM to about 10 mM, or from about 1 mM to about 5 mM, respectively.
  • the buffer is one that is suitable for use with the present invention, i.e., does not prevent the formation of the B-2036 protein component or degrade it once it is formed.
  • Suitable buffers for use in connection with the present invention include, but are not limited to, Tris, phosphate, HEPES, citric acid, triethylamine, and histidine.
  • the preferred buffer is Tris.
  • the preferred initial buffer concentration is from about 1 mM to about 200 mM, more preferably from about 5 mM to about 100 mM, even more preferably from about 8 mM to about 70 mM, and most preferably from about 10 mM to about 50 mM.
  • buffers may be used.
  • these buffers are sufficient to maintain the pH of the growth medium anywhere in the range from about 4 to about 9, from about 7.5 to about 8.5, or from about 7.5 to about 8.0, respectively.
  • higher pH levels for example, as high as about 9.5 may be tolerated.
  • the pH of the buffer may be as high as about 9.5.
  • the amount of the mercapto compound in the buffer should be such that the molar ratio of the moles of mercapto compound to the moles of B-2036 protein is from about 0.5 to about 1,000. This is especially so when the mercapto compound being used is a combination of cysteine and, optionally, cysteine in combination with cystine.
  • the molar ratio of the moles of mercapto compound to the moles of B-2036 protein may be from about 1 to about 1,000, from about 1 to about 500, or from about 1 to about 10, respectively.
  • B-2036 protein component in the buffer has a concentration from about 0.1 mg/ml to about 30 mg/ml, from about 0.5 mg/ml to about 20 mg/ml, or from about 1 mg/ml to about 10 mg/ml, respectively.
  • the temperature range of the growth medium together with the buffer, the mercapto compound(s) and its other contents including, but not limited to, B-2036 should be maintained at a temperature preferably from about 0° C. to about 25° C. after the mercapto compound has been added to the host cell(s) or lysate thereof containing the B-2036 protein component. Also, preferably, the temperature of the host cell(s) and/or lysate therefrom containing the B-2036 component is maintained from about 1° C. to about 15° C., from about 2° C. to about 10° C., or from about 2° C. to about 8° C., respectively. It is important to note that B-2036 protein denaturation occurs at about 40+° C. As such, it is desirable to maintain the temperature of the homogenate (i.e., containing host cells, growth medium, buffer, mercapto compounds and B-2036, etc.) to a temperature below the protein denaturation temperature of B-2036.
  • the homogenate i.e
  • the contact time between the B-2036 component and the mercapto compound should be for a time sufficient to decrease the level of the trisulfide isoform impurity.
  • Exemplary suitable contact times for decreasing the level of the trisulfide isoform impurity should be for at least about 30 minutes, from about 1 hour to about 24 hours, or from about 1 hour to about 4 hours, respectively.
  • the buffer containing the same has a volume from about 1 liter to about 5,000 liters, from about 10 liters to about 500 liters, or from 100 liters to about 300 liters, respectively.
  • Other suitable exemplary volumes may be anywhere from 160 liters to about 500 liters.
  • mixing rate should be that which is sufficient to form a homogenous mixture (of the host cell(s), lysate thereof, buffer, mercapto compound(s), the B-2036 component and any other components in one growth medium) while minimizing the amount of foaming that may be formed.
  • a sufficient mixing rate should be. Obviously, the mixing rate should be such that the temperature is maintained in the above-noted ranges and any degradation of the B-2036 protein component is minimized.
  • the chelating agent(s) is/are added to the host cell(s) synthesizing the desired recombinant B-2036 protein component during or after (or during and after) growth of the host cell(s). Furthermore, after the growing and contacting steps have been conducted, it is preferred to purify the B-2036 protein. Thereafter, the purified protein is preferably pegylated to yield PEG B-2036 (pegvisomant). For pegylation procedures see U.S. Pat. No. 5,849,535.
  • Any chelating agent may be used in connection with the present invention which, when contacted (preferably with adequate mixing) with the B-2036 protein component together with its trisulfide isoform impurity, is one that is sufficient to decrease the level of the trisulfide isoform impurity, preferably without degrading (or substantially degrading) the yield of B-2036.
  • Preferred chelating agents suitable for use with the present invention include, but are not limited to, EDTA, EGTA, and DTPA.
  • Additional exemplary chelating agents include, but are not limited to, Deferoxamine, Ditiocarb Sodium, Edetate Calcium Disodium, Edetate Disodium, Edetate Sodium, Edetate Trisodium, Penicillamine, Pentetate Calcium Trisodium, Pentetic Acid, Succimer, and Trientine. Note that Edetate Sodium is the salt form of EDTA.
  • the amount of chelating agent that is suitable for use with the present invention should be that amount which is sufficient to decrease the trisulfide isoform impurity by at least about 10% of its highest equilibrium concentration (or its highest average equilibrium concentration, where multiple batches are averaged) formed.
  • the decrease in the amount of the trisulfide isoform impurity is least about 20%, 30%, 40%, or 50%, respectively, of its highest equilibrium concentration (or its highest average equilibrium concentration) formed.
  • the initial concentration of EDTA suitable for use with the present invention is preferably at least about 0.01 mM, from about 0.01 mM to about 100 mM, from about 0.1 mM to about 20 mM, from about 2 mM to about 10 mM or from about 2 to about 5 mM, respectively.
  • the buffer is one that is suitable for use with the present invention, i.e., does not prevent the formation of the B-2036 protein component or degrade it once it is formed
  • Suitable buffers for use in connection with the present invention include, but are not limited to, Tris, phosphate, HEPES, citric acid, triethylamine, and histidine.
  • the preferred buffer is Tris.
  • the preferred initial buffer concentration is from about 1 mM to about 200 mM, more preferably from about 5 mM to about 100 mM, even more preferably from about 8 mM to about 70 mM, and most preferably from about 10 mM to about 50 mM.
  • Other suitable buffers may be used.
  • these buffers are sufficient to maintain the pH of the growth medium anywhere in the range from about 6 to about 9, from about 6.5 to about 7.5, or from about 7.2 to about 7.5, respectively.
  • the chelating agent in a buffer.
  • the amount of the chelating agent in the buffer should be such that the molar ratio of the moles of chelating agent to the moles of B-2036 protein is from about 1 to about 1,000.
  • the molar ratio of the moles of chelating agent to the moles of B-2036 protein may be from about 20 to about 1,000, from about 50 to about 250, or from about 60 to about 110, respectively.
  • the B-2036 protein component in the buffer has a concentration from about 0.1 mg/ml to about 20 mg/ml, from about 0.5 mg/ml to about 5 mg/ml, or from about 1 mg/ml to about 5 mg/ml, respectively.
  • the temperature range of the growth medium together with the buffer, the chelating agent(s) and its other contents including, but not limited to, B-2036 should be maintained at a temperature preferably from about 0° C. to about 35° C. after the chelating agent has been added to the host cell(s) or lysate thereof containing the B-2036 protein component. Also, preferably, the temperature of the host cell(s) and/or lysate therefrom containing the B-2036 component is maintained from about 1° C. to about 15° C., from about 2° C. to about 10° C., or from about 2° C. to about 15° C., respectively.
  • the temperature of the homogenate containing the B-2036 rises to about 30° C. upon homogenization. It is important to note that B-2036 protein denaturation occurs at about 40+° C. As such, it is desirable to maintain the temperature of the homogenate (i.e., containing host cells, growth medium, buffer, chelating agents, and B-2036, etc.) to a temperature below the protein denaturation temperature of B-2036.
  • the chelating agent e.g., EDTA
  • the contact time between the B-2036 component and the chelating agent should be for a time sufficient to decrease the level of the trisulfide isoform impurity.
  • Exemplary suitable contact times for decreasing the level of the trisulfide isoform impurity should be for at least about 30 minutes, from about 1 hour to about 48 hours, or from about 5 hours to about 15 hours, respectively.
  • the buffer containing the same has a volume from about 1 liter to about 5,000 liters, from about 10 liters to about 500 liters, or from 100 liters to about 300 liters, respectively.
  • Other suitable exemplary volumes may be anywhere from 160 liters to about 500 liters.
  • mixing rate should be that which is sufficient to form a homogenous mixture (of the host cell(s), lysate thereof, buffer, chelating agent(s), the B-2036 component and any other components in the growth medium) while minimizing the amount of foaming that may be formed.
  • Those of ordinary skill can readily determine what a sufficient mixing rate should be. Obviously, the mixing rate should be such that the temperature is maintained in the above-noted ranges and any degradation of the B-2036 protein component is minimized.
  • the metal salt(s) is/are added to the host cell(s) synthesizing the desired recombinant B-2036 protein component during or after (or during and after) growth of the host cell(s). Furthermore, after the growing and contacting steps have been conducted, it is preferred to purify the B-2036 protein. Thereafter, the purified protein is preferably pegylated to yield PEG B-2036 (pegvisomant). For pegylation procedures see U.S. Pat. No. 5,849,535.
  • Any metal salt may be used in connection with the present invention which, when contacted (preferably with adequate mixing) with the B-2036 protein component together with its trisulfide isoform impurity, is one that is sufficient to decrease the level of the trisulfide isoform impurity, preferably without degrading (or substantially degrading) the yield of B-2036.
  • Metal salt(s) suitable for use with the present invention include, but are not limited to, alkali earth metal salt(s), alkaline earth metal salt(s), transition metal salt(s) and combinations thereof.
  • Preferred metal salts suitable for use with the present invention include, but are not limited to, potassium phosphate, potassium acetate, sodium phosphate, sodium acetate, zinc chloride, and combinations thereof.
  • metal salts for use with the present invention sodium phosphate, ZnCl 2 and combinations thereof are also preferred.
  • the amount of metal salt(s) suitable for use with the present invention should be that amount which is sufficient to decrease the trisulfide isoform impurity by at least about 10% of its highest concentration (or its highest average concentration, where multiple batches are averaged) formed.
  • the decrease in the amount of the trisulfide isoform impurity is least about 20%, 30%, 40%, or 50%, respectively, of its highest concentration (or its highest average concentration) formed.
  • the initial concentration of metal salt (e.g., sodium phosphate) suitable for use with the present invention is preferably at least about 0.1 mM, from about 1 mM to about 500 mM, from about 1 mM to about 200 mM, from about 5 mM to about 175 mM, from about 10 mM to about 150 mM or from about 25 to about 100 mM, respectively.
  • metal salt e.g., sodium phosphate
  • the metal salt in a buffer.
  • sodium phosphate can act both as a buffer and a suitable metal salt.
  • additional suitable metal salt(s) may be added to the sodium phosphate buffer.
  • the buffer is one that is suitable for use with the present invention, i.e., does not prevent the formation of the B-2036 protein component or degrade it once it is formed
  • Suitable buffers for use in connection with the present invention include, but are not limited to, Tris, phosphate, HEPES, citric acid, triethylamine, and histidine.
  • the preferred initial buffer concentration is from about 1 mM to about 200 mM, more preferably from about 5 mM to about 100 mM, even more preferably from about 8 mM to about 70 mM and most preferably from about 10 mM to about 50 mM.
  • Other suitable buffers may be used. Preferably, these buffers are sufficient to maintain the pH of the growth medium anywhere in the range from about 4 to about 9, from about 4.5 to about 7.5, or from about 5.5 to about 7.5, respectively.
  • the amount of the metal salt in the buffer should be such that the molar ratio of the moles of metal salt to the moles of B-2036 protein is from about 1 to about 10,000.
  • the molar ratio of the moles of the metal salt to the moles of B-2036 protein may be from about 300 to about 10,000, from about 500 to about 5,000, or from about 500 to about 2500, respectively.
  • the B-2036 protein component in the buffer has a concentration from about 0.1 mg/ml to about 20 mg/ml, from about 0.5 mg/ml to about 5 mg/ml, or from about 1 mg/ml to about 5 mg/ml, respectively.
  • the temperature range of the growth medium together with the buffer, the metal salt(s) and its other contents including, but not limited to, B-2036 preferably should be maintained at a temperature from about 0° C. to about 35° C. after the metal salt has been added to the host cell(s) or lysate thereof containing the B-2036 protein component. Also, preferably, the temperature of the host cell(s) and/or lysate therefrom containing the B-2036 component is maintained from about 1° C. to about 15° C., from about 2° C. to about 10° C., or from about 2° C. to about 15° C., respectively.
  • the temperature of the homogenate may rise. It is important to note that B-2036 protein denaturation occurs at about 40+° C. As such, it is desirable to maintain the temperature of the homogenate (i.e., containing host cells, growth medium, buffer, metal salt, B-2036, and optionally mercapto compound, etc.) to a temperature below the protein denaturation temperature of B-2036.
  • the metal salt e.g., NaP
  • the contact time between the B-2036 component and the chelating agent should be for a time sufficient to decrease the level of the trisulfide isoform impurity.
  • Exemplary suitable contact times for decreasing the level of the trisulfide isoform impurity should be for at least about 30 minutes, from about 1 hour to about 48 hours, or from about 5 hours to about 15 hours, respectively.
  • the buffer containing the same has a volume from about 1 liter to about 5,000 liters, from about 100 liters to about 2,000 liters, or from 200 liters to about 1,500 liters, respectively.
  • mixing rate should be that which is sufficient to form a homogenous mixture (of the host cell(s), lysate thereof, buffer, metal salt(s), the B-2036 component and any other components in the growth medium) while minimizing the amount of foaming that may be formed.
  • Those of ordinary skill can readily determine what a sufficient mixing rate should be. Obviously, the mixing rate should be such that the temperature is maintained in the above-noted ranges and any degradation of the B-2036 protein component is minimized.
  • the chelating agent(s) is/are added to the host cell(s) synthesizing the desired recombinant B-2036 protein component during or after (or during and after) growth of the host cell(s). Furthermore, after the growing and contacting steps have been conducted, it is preferred to purify the B-2036 protein. Thereafter, the purified protein is preferably pegylated to yield PEG B-2036 (pegvisomant). For pegylation procedures see U.S. Pat. No. 5,849,535.
  • Any chelating agent may be used in connection with the present invention which, when contacted (preferably with adequate mixing) with the B-2036 protein component together with its des-phe isoform impurity, is one that is sufficient to decrease the level of the des-phe isoform impurity, preferably without degrading (or substantially degrading) the yield of B-2036.
  • Preferred chelating agents suitable for use with the present invention include, but are not limited to, EDTA, EGTA, and DTPA.
  • Additional exemplary chelating agents include, but are not limited to, Deferoxamine, Ditiocarb Sodium, Edetate Calcium Disodium, Edetate Disodium, Edetate Sodium, Edetate Trisodium, Penicillamine, Pentetate Calcium Trisodium, Pentetic Acid, Succimer, and Trientine. Note that Edetate Sodium is the salt form of EDTA.
  • the amount of chelating agent that is suitable for use with the present invention should be that amount which is sufficient to decrease the des-phe isoform impurity by at least about 10% of its highest equilibrium concentration (or its highest average equilibrium concentration, where multiple batches are averaged) formed.
  • the decrease in the amount of the des-phe isoform impurity is least about 20%, 30%, 40%, or 50%, respectively, of its highest equilibrium concentration (or its highest average equilibrium concentration) formed.
  • the initial concentration of EDTA suitable for use with the present invention is preferably at least about 0.01 mM, from about 0.01 mM to about 100 mM, from about 0.1 mM to about 20 mM, from about 2 mM to about 10 mM or from about 2 to about 5 mM, respectively.
  • the buffer is one that is suitable for use with the present invention, i.e., does not prevent the formation of the B-2036 protein component or degrade it once it is formed
  • Suitable buffers for use in connection with the present invention include, but are not limited to, Tris, phosphate, HEPES, citric acid, triethylamine, and histidine.
  • the preferred buffer is Tris.
  • the preferred initial buffer concentration is from about 1 mM to about 200 mM, more preferably from about 5 mM to about 100 mM, even more preferably from about 8 mM to about 70 mM, and most preferably from about 10 mM to about 50 mM.
  • Other suitable buffers may be used.
  • these buffers are sufficient to maintain the pH of the growth medium anywhere in the range from about 6 to about 9, from about 6.5 to about 7.5, or from about 7.2 to about 7.5, respectively.
  • the chelating agent in a buffer.
  • the amount of the chelating agent in the buffer should be such that the molar ratio of the moles of chelating agent to the moles of B-2036 protein is from about 1 to about 1,000.
  • the molar ratio of the moles of chelating agent to the moles of B-2036 protein may be from about 20 to about 1,000, from about 50 to about 250, or from about 60 to about 110, respectively.
  • the B-2036 protein component in the buffer has a concentration from about 0.1 mg/ml to about 20 mg/ml, from about 0.5 mg/ml to about 5 mg/ml, or from about 1 mg/ml to about 5 mg/ml, respectively.
  • the temperature range of the growth medium together with the buffer, the chelating agent(s) and its other contents including, but not limited to, B-2036 should be maintained at a temperature preferably from about 0° C. to about 35° C. after the chelating agent has been added to the host cell(s) or lysate thereof containing the B-2036 protein component. Also, preferably, the temperature of the host cell(s) and/or lysate therefrom containing the B-2036 component is maintained from about 1° C. to about 15° C., from about 2° C. to about 10° C., or from about 2° C. to about 15° C., respectively.
  • the temperature of the homogenate containing the B-2036 rises to about 30° C. upon homogenization. It is important to note that B-2036 protein denaturation occurs at about 40+° C. As such, it is desirable to maintain the temperature of the homogenate (i.e., containing host cells, growth medium, buffer, chelating agents, and B-2036, etc.) to a temperature below the protein denaturation temperature of B-2036.
  • the chelating agent e.g., EDTA
  • the contact time between the B-2036 component and the chelating agent should be for a time sufficient to decrease the level of the des-phe isoform impurity.
  • Exemplary suitable contact times for decreasing the level of the des-phe isoform impurity should be for at least about 30 minutes, from about 1 hour to about 48 hours, or from about 5 hours to about 15 hours, respectively.
  • the buffer containing the same has a volume from about 1 liter to about 5,000 liters, from about 10 liters to about 500 liters, or from 100 liters to about 300 liters, respectively.
  • Other suitable exemplary volumes may be anywhere from 160 liters to about 500 liters.
  • the mixing rate should be that which is sufficient to form a homogenous mixture (of the host cell(s), lysate thereof, buffer, chelating agent(s), the B-2036 component and any other components in the growth medium) while minimizing the amount of foaming that may be formed.
  • Those of ordinary skill can readily determine what a sufficient mixing rate should be. Obviously, the mixing rate should be such that the temperature is maintained in the above-noted ranges and any degradation of the B-2036 protein component is minimized.
  • the metal salt(s) is/are added to the host cell(s) synthesizing the desired recombinant B-2036 protein component during or after (or during and after) growth of the host cell(s). Furthermore, after the growing and contacting steps have been conducted, it is preferred to purify the B-2036 protein. Thereafter, the purified protein is preferably pegylated to yield PEG B-2036 (pegvisomant). For pegylation procedures see U.S. Pat. No. 5,849,535.
  • Any metal salt may be used in connection with the present invention which, when contacted (preferably with adequate mixing) with the B-2036 protein component together with its des-phe isoform impurity, is one that is sufficient to decrease the level of the des-phe isoform impurity, preferably without degrading (or substantially degrading) the yield of B-2036.
  • Metal salt(s) suitable for use with the present invention include, but are not limited to, alkali earth metal salt(s), alkaline earth metal salt(s), transition metal salt(s) and combinations thereof.
  • Preferred metal salts suitable for use with the present invention include, but are not limited to, potassium phosphate, potassium acetate, sodium phosphate, sodium acetate, zinc chloride, and combinations thereof.
  • metal salts for use with the present invention sodium phosphate, ZnCl 2 and combinations thereof are also preferred.
  • the amount of metal salt(s) suitable for use with the present invention should be that amount which is sufficient to decrease the des-phe isoform impurity by at least about 10% of its highest concentration (or its highest average concentration, where multiple batches are averaged) formed.
  • the decrease in the amount of the des-phe isoform impurity is least about 20%, 30%, 40%, or 50%, respectively, of its highest concentration (or its highest average concentration) formed.
  • the initial concentration of metal salt (e.g., sodium phosphate) suitable for use with the present invention is preferably at least about 0.1 mM, from about 1 mM to about 500 mM, from about 1 mM to about 200 mM, from about 5 mM to about 175 mM, from about 10 mM to about 150 mM or from about 25 to about 100 mM, respectively.
  • metal salt e.g., sodium phosphate
  • the metal salt in a buffer.
  • sodium phosphate can act both as a buffer and a suitable metal salt.
  • additional suitable metal salt(s) may be added to the sodium phosphate buffer.
  • the buffer is one that is suitable for use with the present invention, i.e., does not degrade the formation of the B-2036 protein component.
  • Suitable buffers for use in connection with the present invention include, but are not limited to, Tris, phosphate, HEPES, citric acid, triethylamine, and histidine.
  • the preferred initial buffer concentration is from about 1 mM to about 200 mM, more preferably from about 5 mM to about 100 mM, even more preferably from about 8 mM to about 70 mM and most preferably from about 10 mM to about 50 mM.
  • Other suitable buffers may be used. Preferably, these buffers are sufficient to maintain the pH of the growth medium anywhere in the range from about 4 to about 9, from about 4.5 to about 7.5, or from about 5.5 to about 7.5, respectively.
  • the amount of the metal salt in the buffer should be such that the molar ratio of the moles of metal salt to the moles of B-2036 protein is from about 1 to about 10,000.
  • the molar ratio of the moles of the metal salt to the moles of B-2036 protein may be from about 300 to about 10,000, from about 500 to about 5,000, or from about 500 to about 2500, respectively.
  • the B-2036 protein component in the buffer has a concentration from about 0.1 mg/ml to about 20 mg/ml, from about 0.5 mg/ml to about 5 mg/ml, or from about 1 mg/ml to about 5 mg/ml, respectively.
  • the temperature range of the growth medium together with the buffer, the metal salt(s) and its other contents including, but not limited to, B-2036 preferably should be maintained at a temperature from about 0° C. to about 35° C. after the metal salt has been added to the host cell(s) or lysate thereof containing the B-2036 protein component. Also preferably, the temperature of the host cell(s) and/or lysate therefrom containing the B-2036 component is maintained from about 1° C. to about 15° C., from about 2° C. to about 10° C., or from about 2° C. to about 15° C., respectively. Note that upon homogenization with the metal salt (e.g., NaP), the temperature of the homogenate may rise.
  • the metal salt e.g., NaP
  • B-2036 protein denaturation occurs at about 40+° C. As such, it is desirable to maintain the temperature of the homogenate (i.e., containing host cells, growth medium, buffer, metal salt, B-2036, and optionally mercapto compound, etc.) to a temperature below the protein denaturation temperature of B-2036.
  • the homogenate i.e., containing host cells, growth medium, buffer, metal salt, B-2036, and optionally mercapto compound, etc.
  • the contact time between the B-2036 component and the metal salt should be for a time sufficient to decrease the level of the des-phe isoform impurity.
  • Exemplary suitable contact times for decreasing the level of the des-phe isoform impurity should be for at least about 30 minutes, from about 1 hour to about 48 hours, or from about 5 hours to about 15 hours, respectively.
  • the buffer containing the same has a volume from about 1 liter to about 5,000 liters, from about 100 liters to about 2,000 liters, or from 200 liters to about 1,500 liters, respectively.
  • mixing rate should be that which is sufficient to form a homogenous mixture (of the host cell(s), lysate thereof, buffer, metal salt(s), the B-2036 component and any other components in the growth medium) while minimizing the amount of foaming that may be formed.
  • Those of ordinary skill can readily determine what a sufficient mixing rate should be. Obviously, the mixing rate should be such that the temperature is maintained in the above-noted ranges and any degradation of the B-2036 protein component is minimized.
  • the chelating agent(s) is/are added to the host cell(s) synthesizing the desired recombinant growth hormone protein during or after (or during and after) growth of the host cell(s). Furthermore, after the growing and contacting steps have been conducted, it is preferred to purify the growth hormone protein.
  • Any chelating agent may be used in connection with the present invention which, when contacted (preferably with adequate mixing) with the growth hormone protein together with its des-phe isoform impurity, is one that is sufficient to decrease the level of the des-phe isoform impurity, preferably without degrading (or substantially degrading) the yield of the growth hormone.
  • Preferred chelating agents suitable for use with the present invention include, but are not limited to, EDTA, EGTA, and DTPA.
  • Additional exemplary chelating agents include, but are not limited to, Deferoxamine, Ditiocarb Sodium, Edetate Calcium Disodium, Edetate Disodium, Edetate Sodium, Edetate Trisodium, Penicillamine, Pentetate Calcium Trisodium, Pentetic Acid, Succimer, and Trientine. Note that Edetate Sodium is the salt form of EDTA.
  • the amount of chelating agent that is suitable for use with the present invention should be that amount which is sufficient to decrease the des-phe isoform impurity by at least about 10% of its highest equilibrium concentration (or its highest average equilibrium concentration, where multiple batches are averaged) formed.
  • the decrease in the amount of the des-phe isoform impurity is least about 20%, 30%, 40%, or 50%, respectively, of its highest equilibrium concentration (or its highest average equilibrium concentration) formed.
  • the initial concentration of EDTA suitable for use with the present invention is preferably at least about 0.01 mM, from about 0.01 mM to about 100 mM, from about 0.1 mM to about 20 mM, from about 2 mM to about 10 mM or from about 2 to about 5 mM, respectively.
  • the buffer is one that is suitable for use with the present invention, i.e., does not prevent the formation of the B-2036 protein component or degrade it once it is formed.
  • Suitable buffers for use in connection with the present invention include, but are not limited to, Tris, phosphate, HEPES, citric acid, triethylamine, and histidine.
  • the preferred buffer is Tris.
  • the preferred initial buffer concentration is from about 1 mM to about 200 mM, more preferably from about 5 mM to about 100 mM, even more preferably from about 8 mM to about 70 mM, and most preferably from about 10 mM to about 50 mM.
  • Other suitable buffers may be used.
  • these buffers are sufficient to maintain the pH of the growth medium anywhere in the range from about 6 to about 9, from about 6.5 to about 7.5, or from about 7.2 to about 7.5, respectively.
  • the chelating agent in a buffer.
  • the amount of the chelating agent in the buffer should be such that the molar ratio of the moles of chelating agent to the moles of growth hormone protein (e.g., hGH) is from about 1 to about 1,000.
  • the molar ratio of the moles of chelating agent to the moles of growth hormone protein (e.g., hGH) may be from about 20 to about 1,000, from about 50 to about 250, or from about 60 to about 110, respectively.
  • the growth hormone protein (e.g., hGH) in the buffer has a concentration from about 0.1 mg/ml to about 20 mg/ml, from about 0.5 mg/ml to about 5 mg/ml, or from about 1 mg/ml to about 5 mg/ml, respectively.
  • the temperature range of the growth medium together with the buffer, the chelating agent(s) and its other contents including, but not limited to, the growth hormone protein preferably should be maintained at a temperature preferably from about 0° C. to about 35° C. after the chelating agent has been added to the host cell(s) or lysate thereof containing the growth hormone protein. Also, preferably, the temperature of the host cell(s) and/or lysate therefrom containing the growth hormone protein is maintained from about 1° C. to about 15° C., from about 2° C. to about 10° C., or from about 2° C. to about 15° C., respectively.
  • the temperature of the homogenate containing the growth hormone rises to about 30° C. upon homogenization. It is important to note that growth hormone protein denaturation occurs at about 40+° C. As such, it is desirable to maintain the temperature of the homogenate (i.e., containing host cells, growth medium, buffer, chelating agents, and growth hormone protein, etc.) to a temperature below the protein denaturation temperature of growth hormone protein.
  • the chelating agent e.g., EDTA
  • the contact time between the growth hormone protein and the chelating agent should be for a time sufficient to decrease the level of the des-phe isoform impurity.
  • Exemplary suitable contact times for decreasing the level of the des-phe isoform impurity should be for at least about 30 minutes, from about 1 hour to about 48 hours, or from about 5 hours to about 15 hours, respectively.
  • the buffer containing the same has a volume from about 1 liter to about 5,000 liters, from about 10 liters to about 500 liters, or from 100 liters to about 300 liters, respectively.
  • Other suitable exemplary volumes may be anywhere from 160 liters to about 500 liters.
  • mixing rate should be that which is sufficient to form a homogenous mixture (of the host cell(s), lysate thereof, buffer, chelating agent(s), the growth hormone protein and any other components in the growth medium) while minimizing the amount of foaming that may be formed.
  • Those of ordinary skill can readily determine what a sufficient mixing rate should be. Obviously, the mixing rate should be such that the temperature is maintained in the above-noted ranges and any degradation of the growth hormone protein component is minimized.
  • the metal salt(s) is/are added to the host cell(s) synthesizing the desired recombinant growth hormone protein component during or after (or during and after) growth of the host cell(s). Furthermore, after the growing and contacting steps have been conducted, it is preferred to purify the growth hormone protein.
  • Any metal salt may be used in connection with the present invention which, when contacted (preferably with adequate mixing) with the growth hormone protein component together with its des-phe isoform impurity, is one that is sufficient to decrease the level of the des-phe isoform impurity, preferably without degrading (or substantially degrading) the yield of growth hormone.
  • Metal salt(s) suitable for use with the present invention include, but are not limited to, alkali earth metal salt(s), alkaline earth metal salt(s), transition metal salt(s) and combinations thereof.
  • Preferred metal salts suitable for use with the present invention include, but are not limited to, potassium phosphate, potassium acetate, sodium phosphate, sodium acetate, zinc chloride, and combinations thereof.
  • metal salts for use with the present invention sodium phosphate, ZnCl 2 and combinations thereof are also preferred.
  • the amount of metal salt(s) suitable for use with the present invention should be that amount which is sufficient to decrease the des-phe isoform impurity by at least about 10% of its highest concentration (or its highest average concentration, where multiple batches are averaged) formed.
  • the decrease in the amount of the des-phe isoform impurity is least about 20%, 30%, 40%, or 50%, respectively, of its highest concentration (or its highest average concentration) formed.
  • the initial concentration of metal salt (e.g., sodium phosphate) suitable for use with the present invention is preferably at least about 0.1 mM, from about 1 mM to about 500 mM, from about 1 mM to about 200 mM, from about 5 mM to about 175 mM, from about 10 mM to about 150 mM or from about 25 to about 100 mM, respectively.
  • metal salt e.g., sodium phosphate
  • the metal salt in a buffer.
  • sodium phosphate can act both as a buffer and a suitable metal salt.
  • additional suitable metal salt(s) may be added to the sodium phosphate buffer.
  • the buffer is one that is suitable for use with the present invention, i.e., does not prevent the formation of the B-2036 protein component or degrade it once it is formed
  • Suitable buffers for use in connection with the present invention include, but are not limited to, Tris, phosphate, HEPES, citric acid, triethylamine, and histidine.
  • the preferred initial buffer concentration is from about 1 mM to about 200 mM, more preferably from about 5 mM to about 100 mM, even more preferably from about 8 mM to about 70 mM and most preferably from about 10 mM to about 50 mM.
  • Other suitable buffers may be used. Preferably, these buffers are sufficient to maintain the pH of the growth medium anywhere in the range from about 4 to about 9, from about 4.5 to about 7.5, or from about 5.5 to about 7.5, respectively.
  • the amount of the metal salt in the buffer should be such that the molar ratio of the moles of metal salt to the moles of growth hormone protein (e.g., hGH) is from about 1 to about 10,000.
  • the molar ratio of the moles of the metal salt to the moles of growth hormone protein (e.g., hGH) may be from about 300 to about 10,000, from about 500 to about 5,000, or from about 500 to about 2500, respectively.
  • the growth hormone protein in the buffer has a concentration from about 0.1 mg/ml to about 20 mg/ml, from about 0.5 mg/ml to about 5 mg/ml, or from about 1 mg/ml to about 5 mg/ml, respectively.
  • the temperature range of the growth medium together with the buffer, the metal salt(s) and its other contents including, but not limited to, the growth hormone protein preferably should be maintained at a temperature from about 0° C. to about 35° C. after the metal salt has been added to the host cell(s) or lysate thereof containing the growth hormone protein. Also, preferably, the temperature of the host cell(s) and/or lysate therefrom containing the growth hormone protein is maintained from about 1° C. to about 15° C., from about 2° C. to about 10° C., or from about 2° C. to about 15° C., respectively. Note that upon homogenization with the metal salt (e.g., NaP), the temperature of the homogenate may rise.
  • the metal salt e.g., NaP
  • growth hormone protein denaturation occurs at about 40+° C. As such, it is desirable to maintain the temperature of the homogenate (i.e., containing host cells, growth medium, buffer, metal salt, growth hormone protein, and optionally mercapto compound, etc.) to a temperature below the protein denaturation temperature of growth hormone protein.
  • the homogenate i.e., containing host cells, growth medium, buffer, metal salt, growth hormone protein, and optionally mercapto compound, etc.
  • the contact time between the growth hormone protein and the metal salt should be for a time sufficient to decrease the level of the des-phe isoform impurity.
  • Exemplary suitable contact times for decreasing the level of the des-phe isoform impurity should be for at least about 30 minutes, from about 1 hour to about 48 hours, or from about 5 hours to about 15 hours, respectively.
  • the buffer containing the same has a volume from about 1 liter to about 5,000 liters, from about 100 liters to about 2,000 liters, or from 200 liters to about 1,500 liters, respectively.
  • mixing rate should be that which is sufficient to form a homogenous mixture (of the host cell(s), lysate thereof, buffer, metal salt(s), the growth hormone protein and any other components in the growth medium) while minimizing the amount of foaming that may be formed.
  • Those of ordinary skill can readily determine what a sufficient mixing rate should be. Obviously, the mixing rate should be such that the temperature is maintained in the above-noted ranges and any degradation of the growth hormone protein component is minimized.
  • a process for decreasing the amount of an impurity produced in recombinant production of a growth hormone antagonist polypeptide in genetically modified host cells comprising the step of:
  • said impurity is a trisulfide isoform of said polypeptide.
  • said impurity is a trisulfide isoform of said polypeptide.
  • said impurity is a trisulfide isoform of said polypeptide.
  • said impurity is a des-phe isoform of said polypeptide.
  • said impurity is a des-phe isoform of said polypeptide.
  • said impurity is a des-phe isoform of said polypeptide.
  • said impurity is a des-phe isoform of said polypeptide.
  • Reduction of B-2036-trisulfide level was accomplished using Retentate 1 (see flowchart 1 below) in the B-2036 purification process. Fermentation of the recombinant E. coli expressing B-2036 was carried out as described by Cunningham et al. in U.S. Pat. No. 5,849,535. The initial extraction and purification steps (all steps conducted prior to obtaining Retentate 1 in flowchart 1 below, e.g., all resuspension and homogenization, two-phase extraction, reversed phase chromatography, and anion exchange chromatography) were carried out as described in the accompanying flowchart 1.
  • the product was present in 25 mM HEPES, pH 7.0 buffer ( ⁇ 150 L) at a protein concentration of 3.7 g/L.
  • the temperature of the product solution was cooled to 2 to 8° C. and it was treated with a 1/10 th volume addition ( ⁇ 15 L) of freshly prepared 200 mM Tris, 20 mM cysteine, pH 8.0 buffer that had been cooled to 2 to 8° C.
  • the B-2036/cysteine solution was maintained at 2 to 8° C. and mixed for 174 minutes.
  • the mixture was then concentrated to 131 L using Millipore Biomax 5 ultrafiltration membranes and diafiltered against a 6 ⁇ volume of 25 mM HEPES, pH 7.0.
  • the resulting product was then carried through the remainder of the B-2036 purification process as described in flowchart 1 below.
  • the B-2036/trisulfide level was measured to be 3.7 area percent. Immediately after the cysteine incubation, its level dropped to 2.0 area percent (decreased by about 46%).
  • the resulting two-phase mixture was mixed for 60-120 minutes and then these phases were resolved by passing the solution through a liquid/liquid, solids discharging centrifuge.
  • the top phase contained the desired product and was collected and filtered through a filter train consisting of a “delipidating” filter, “depth” filter, and a 0.2 ⁇ m filter.
  • the filtrate was collected in three separate totes and samples of each were analyzed for B-2036-trisulfide. The levels ranged from 3.1 to 3.8 area percent.
  • the resulting material was then processed to bulk intermediate using the procedure outlined in the flowchart of Example #1.
  • a trisulfide level at the end of the entire process of flowchart 1 was 1.5% area percent.
  • the resulting two-phase mixture was mixed for 60-120 minutes and then these phases were resolved by passing the solution through a liquid/liquid, solids discharging centrifuge.
  • the top phase contained the desired product and was collected and filtered through a filter train consisting of a “delipidating” filter, a “depth” filter, and a 0.2 ⁇ /m filter.
  • the material was carried through the remainder of the B-2036 process as described in flowchart 2 below.
  • the resulting two-phase mixture was mixed for 60-120 minutes and then these phases were resolved by passing the solution through a liquid/liquid, solids discharging centrifuge.
  • the top phase contained the desired product and was collected and filtered through a filter train consisting of a “delipidating” filter, a “depth” filter, and a 0.2 ⁇ m filter.
  • the filtrate (obtained after top phase filtration; see flowchart 1) was collected in three separate totes and samples of each were analyzed for B-2036/des-phe. The levels ranged from 3.2 to 6.3 area percent. For comparison, further processing according to flowchart 1 further reduced the B-2036 des-phe level to 0.3 area percent of Retentate 3.
  • B-2036 des-phe level was achieved by the product collection parameters of the second anion exchange chromatography step.
  • the resulting two-phase mixture was mixed for 60-120 minutes and then these phases were resolved by passing the solution through a liquid/liquid, solids discharging centrifuge.
  • the top phase contained the desired product and was collected and filtered through a filter train consisting of a “delipidating” filter, a “depth” filter, and a 0.2 ⁇ m filter.
  • the filtrate was collected in three separate totes and samples of each were analyzed for B-2036/des-phe. The levels ranged from 6.0 to 9.4 area percent.
  • further processing according to flowchart 2 further reduced the B-2036/des-phe level to 0.8 area percent of Retentate 2. This further reduction of B-2036/des-phe level was achieved by the product collection parameters following the second anion exchange chromatography step.
  • sodium phosphate e.g. 150 mM Tris, pH 7.2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US10/646,798 2002-08-28 2003-08-25 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof Abandoned US20040048315A1 (en)

Priority Applications (45)

Application Number Priority Date Filing Date Title
US10/646,798 US20040048315A1 (en) 2002-08-28 2003-08-25 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
EP03799266A EP1546185B1 (en) 2002-08-28 2003-08-26 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
RU2005109388/13A RU2337920C2 (ru) 2002-08-28 2003-08-26 Способ получения рекомбинантного полипептида-антагониста соматотропного гормона со сниженным содержанием изоформных примесей (варианты)
SI200331584T SI1546185T1 (sl) 2002-08-28 2003-08-26 Postopek priprave rastnega hormona in njegovega antagonista, ki ima nižje nivoje izoformnih nečistoč le-tega
BRPI0313829-1A BRPI0313829B1 (pt) 2002-08-28 2003-08-26 Processo para diminuir a quantidade de uma impureza isoforma de trissulfeto produzida na produção recombinante de b-2036 de seq id no. 1 em células hospedeiras geneticamente modificadas
MXPA05002359A MXPA05002359A (es) 2002-08-28 2003-08-26 Metodo para la preparacion de hormona de crecimiento y antagonista de la misma que tiene menores niveles de impurezas isoforma de la misma.
CN03824791.7A CN1697839B (zh) 2002-08-28 2003-08-26 同工型杂质水平较低的生长激素及其拮抗剂的制备方法
CA2497146A CA2497146C (en) 2002-08-28 2003-08-26 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
PT03799266T PT1546185E (pt) 2002-08-28 2003-08-26 Método para a preparação de hormona do crescimento e seus antagonistas apresentando níveis inferiores de suas impurezas isoformas
KR1020057003458A KR101176588B1 (ko) 2002-08-28 2003-08-26 성장 호르몬 및 낮은 수준의 이성체 불순물을 갖는 성장 호르몬 대항제의 제조 방법
PL374917A PL211502B1 (pl) 2002-08-28 2003-08-26 Sposób obniżania zawartości zanieczyszczenia oznaczającego trisiarczkową izoformę, powstającego podczas rekombinacyjnego wytwarzania polipeptydu B-2036
JP2004541486A JP4312154B2 (ja) 2002-08-28 2003-08-26 アイソフォーム不純物のレベルがより低い成長ホルモン及びそのアンタゴニストの調製方法
AT03799266T ATE428721T1 (de) 2002-08-28 2003-08-26 Verfahren zur herstellung von wachstumshormon und antagonisten davon mit geringeren konzentrationen an isoformen verunreinigungen davon
ES03799266T ES2323586T3 (es) 2002-08-28 2003-08-26 Procedimiento de preparacion de hormona del crecimiento y antagonista de la misma que tiene niveles inferiores de impurezas de isoformas.
DE60327228T DE60327228D1 (de) 2002-08-28 2003-08-26 Verfahren zur herstellung von wachstumshormon und antagonisten davon mit geringeren konzentrationen an isoformen verunreinigungen davon
DK03799266T DK1546185T3 (da) 2002-08-28 2003-08-26 Fremgangsmåde til fremstilling af væksthormon og antagonist deraf med lavere niveauer af isoform-urenheder deraf
PCT/US2003/026498 WO2004031213A1 (en) 2002-08-28 2003-08-26 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
AU2003260045A AU2003260045B2 (en) 2002-08-28 2003-08-26 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
TW095130368A TW200700553A (en) 2002-08-28 2003-08-28 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
TW092123686A TWI289603B (en) 2002-08-28 2003-08-28 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
ARP030103444 AR041350A1 (es) 2002-09-20 2003-09-22 Proceso para reducir los niveles de agregados de proteinas tratadas con peg
PT03754774T PT1545428E (pt) 2002-09-20 2003-09-22 Processo para diminuir o nível da agregação de uma proteína peguilada
TW92126051A TWI318629B (en) 2002-09-20 2003-09-22 Process for decreasing aggregate levels of pegylated protein
CN038253097A CN1703421B (zh) 2002-09-20 2003-09-22 降低peg化蛋白的聚集体水平的方法
DK03754774.2T DK1545428T3 (da) 2002-09-20 2003-09-22 Fremgangsmåde til formindskelse af aggregatmængder af pegylerede proteiner
DE60330787T DE60330787D1 (de) 2002-09-20 2003-09-22 Verfahren zur verringerung der aggregatmengen des pegylierten proteins
SI200331730T SI1545428T1 (sl) 2002-09-20 2003-09-22 Postopek zniževanja agregatnih nivojev pegiliranega proteina
AT03754774T ATE453662T1 (de) 2002-09-20 2003-09-22 Verfahren zur verringerung der aggregatmengen des pegylierten proteins
PCT/US2003/029546 WO2004026251A2 (en) 2002-09-20 2003-09-22 Process for decreasing aggregate levels of pegylated protein
PL375443A PL212726B1 (pl) 2002-09-20 2003-09-22 Sposób obnizenia poziomu agregatu polietylenoglikolowanego antagonisty hormonu wzrostu B-2036 i jego izoform
MXPA05003121A MXPA05003121A (es) 2002-09-20 2003-09-22 Procedimiento para disminuir los niveles de agregados de proteina polietilenglicosilada.
RU2005113152/13A RU2368619C2 (ru) 2002-09-20 2003-09-22 Способ получения соматотропного гормона со сниженным содержанием агрегата его изоформ, способ получения антагониста соматотропного гормона со сниженным содержанием агрегата его изоформ и общим суммарным содержанием трисульфидной примеси и/или дефенилаланиновой примеси
EP03754774A EP1545428B1 (en) 2002-09-20 2003-09-22 Process for decreasing aggregate levels of pegylated protein
KR1020057004785A KR101120130B1 (ko) 2002-09-20 2003-09-22 피이지화 단백질의 응집물 수준을 감소시키기 위한 공정
ES03754774T ES2337041T3 (es) 2002-09-20 2003-09-22 Procedimiento para disminuir los niveles de agregacion de proteina pegilada.
BRPI0314120A BRPI0314120B8 (pt) 2002-09-20 2003-09-22 processo para diminuição de um nível de agregado de um antagonista de hormônio do crescimento (gh) peguilado e isoformas do mesmo
CA2498886A CA2498886C (en) 2002-09-20 2003-09-22 Process for decreasing aggregate levels of pegylated protein
AU2003272585A AU2003272585B2 (en) 2002-09-20 2003-09-22 Process for decreasing aggregate levels of pegylated protein
JP2004538262A JP4633463B2 (ja) 2002-09-20 2003-09-22 Ｐｅｇ化タンパク質の凝集レベルを低下させるための方法
IL167121A IL167121A (en) 2002-08-28 2005-02-27 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
IL167538A IL167538A (en) 2002-09-20 2005-03-20 A process for reducing the level of the pegilated growth hormone antibody aggregate
HK05111804.8A HK1077074A1 (en) 2002-08-28 2005-12-21 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
HK05112085.6A HK1079798B (zh) 2002-09-20 2005-12-29 降低peg化蛋白的聚集體水平的方法
US12/405,857 US8148331B2 (en) 2002-08-28 2009-03-17 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
CY20091100660T CY1109167T1 (el) 2002-08-28 2009-06-24 Μεθοδος για την παρασκευη αυξητικης ορμονης και ανταγωνιστη αυτης εχοντας χαμηλοτερα επιπεδα ισομορφικων προσμειξεων αυτου

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40655302P 2002-08-28 2002-08-28
US10/646,798 US20040048315A1 (en) 2002-08-28 2003-08-25 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/405,857 Continuation US8148331B2 (en) 2002-08-28 2009-03-17 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof

Publications (1)

Publication Number Publication Date
US20040048315A1 true US20040048315A1 (en) 2004-03-11

Family

ID=31997673

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/646,798 Abandoned US20040048315A1 (en) 2002-08-28 2003-08-25 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
US12/405,857 Expired - Fee Related US8148331B2 (en) 2002-08-28 2009-03-17 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/405,857 Expired - Fee Related US8148331B2 (en) 2002-08-28 2009-03-17 Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof

Country Status (21)

Country Link
US (2) US20040048315A1 (ko)
EP (1) EP1546185B1 (ko)
JP (1) JP4312154B2 (ko)
KR (1) KR101176588B1 (ko)
AT (1) ATE428721T1 (ko)
AU (1) AU2003260045B2 (ko)
BR (1) BRPI0313829B1 (ko)
CA (1) CA2497146C (ko)
CY (1) CY1109167T1 (ko)
DE (1) DE60327228D1 (ko)
DK (1) DK1546185T3 (ko)
ES (1) ES2323586T3 (ko)
HK (1) HK1077074A1 (ko)
IL (1) IL167121A (ko)
MX (1) MXPA05002359A (ko)
PL (1) PL211502B1 (ko)
PT (1) PT1546185E (ko)
RU (1) RU2337920C2 (ko)
SI (1) SI1546185T1 (ko)
TW (2) TWI289603B (ko)
WO (1) WO2004031213A1 (ko)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069940A1 (en) * 2004-12-29 2006-07-06 Novo Nordisk Health Care Ag Method for preventing formation of trisulfide derivatives of polypeptides
AU2010332959B2 (en) * 2009-12-18 2015-08-06 Csl Ltd. Method of purifying polypeptides
US9790533B2 (en) 2011-05-13 2017-10-17 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
CN109154014A (zh) * 2016-05-10 2019-01-04 豪夫迈·罗氏有限公司 重组产生多肽期间减少三硫键的方法
US10308706B2 (en) 2009-10-02 2019-06-04 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048315A1 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
EP2748178B1 (en) 2011-08-25 2018-10-31 F. Hoffmann-La Roche AG Cation and anion exchange chromatography method
WO2016014360A1 (en) 2014-07-24 2016-01-28 Genentech, Inc. Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5969109A (en) 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DK44593D0 (da) * 1993-04-20 1993-04-20 Novo Nordisk As Fremgangsmaade til fremstilling af et polypeptid
ZA955789B (en) * 1994-07-15 1996-03-11 Novo Nordisk As A method of converting a hydrophobic derivative of a polypeptide into the native form
SE9802454D0 (sv) * 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
AR026743A1 (es) * 1999-12-09 2003-02-26 Pharmacia Ab Produccion de peptidos
US7229789B1 (en) 2001-01-19 2007-06-12 N.V. Organon Methods and compositions for extracting proteins from cells
US20040048315A1 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
ZA200502320B (en) * 2002-09-20 2006-10-25 Pharmacia Corp Process for decreasing aggregate levels of pegylated protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
US6057292A (en) * 1995-09-21 2000-05-02 Genentech, Inc. Method for inhibiting growth hormone action

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069940A1 (en) * 2004-12-29 2006-07-06 Novo Nordisk Health Care Ag Method for preventing formation of trisulfide derivatives of polypeptides
US20090131311A1 (en) * 2004-12-29 2009-05-21 Novo Nordisk Healthcare Ag Method for Preventing Formation of Trisulfide Derivatives of Polypeptides
US8530191B2 (en) 2004-12-29 2013-09-10 Novo Nordisk A/S Method for preventing formation of trisulfide derivatives of polypeptides
US10308706B2 (en) 2009-10-02 2019-06-04 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
AU2010332959B2 (en) * 2009-12-18 2015-08-06 Csl Ltd. Method of purifying polypeptides
US9790533B2 (en) 2011-05-13 2017-10-17 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
US10590454B2 (en) 2011-05-13 2020-03-17 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
CN109154014A (zh) * 2016-05-10 2019-01-04 豪夫迈·罗氏有限公司 重组产生多肽期间减少三硫键的方法
CN114703244A (zh) * 2016-05-10 2022-07-05 豪夫迈·罗氏有限公司 重组产生多肽期间减少三硫键的方法

Also Published As

Publication number Publication date
HK1077074A1 (en) 2006-02-03
PL211502B1 (pl) 2012-05-31
DE60327228D1 (de) 2009-05-28
IL167121A (en) 2010-11-30
US8148331B2 (en) 2012-04-03
BR0313829A (pt) 2005-07-26
RU2337920C2 (ru) 2008-11-10
ES2323586T3 (es) 2009-07-21
EP1546185A4 (en) 2006-09-06
EP1546185B1 (en) 2009-04-15
CA2497146C (en) 2012-05-22
BRPI0313829B1 (pt) 2021-10-26
DK1546185T3 (da) 2009-06-22
ATE428721T1 (de) 2009-05-15
AU2003260045A1 (en) 2004-04-23
WO2004031213A1 (en) 2004-04-15
US20100021966A1 (en) 2010-01-28
CA2497146A1 (en) 2004-04-15
PL374917A1 (en) 2005-11-14
AU2003260045B2 (en) 2010-01-07
JP2006517091A (ja) 2006-07-20
KR101176588B1 (ko) 2012-08-23
CY1109167T1 (el) 2014-07-02
RU2005109388A (ru) 2005-10-27
JP4312154B2 (ja) 2009-08-12
TW200407428A (en) 2004-05-16
PT1546185E (pt) 2009-07-14
MXPA05002359A (es) 2005-07-15
TW200700553A (en) 2007-01-01
EP1546185A1 (en) 2005-06-29
SI1546185T1 (sl) 2009-08-31
KR20050059163A (ko) 2005-06-17
TWI289603B (en) 2007-11-11

Similar Documents

Publication Publication Date Title
US8148331B2 (en) Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
US20050085631A1 (en) Process for decreasing aggregate levels of pegylated protein
Kopchick Discovery and mechanism of action of pegvisomant
US6936437B2 (en) Methods and compositions for production of recombinant peptides
US20110118183A1 (en) N-glycosylated human growth hormone with prolonged circulatory half-life
EP1194445B1 (en) Methods for purifying recombinant growth hormone antagonist proteins using aqueous two-phase extraction
CA2663416A1 (en) High pressure treatment of proteins for reduced immunogenicity
JP4633463B2 (ja) Ｐｅｇ化タンパク質の凝集レベルを低下させるための方法
CN1697839B (zh) 同工型杂质水平较低的生长激素及其拮抗剂的制备方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHARMACIA CORPORATION, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RATHORE, ANURAG S.;LYLE, STEPHEN B.;STEINMEYER, DAVID E.;AND OTHERS;REEL/FRAME:017758/0871;SIGNING DATES FROM 20060517 TO 20060602

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION